Endo International plc (ENDPQ)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Blaise A. Coleman
Employees:
3,100
MINERVA HOUSE, SIMMONSCOURT ROAD, BALLSBRIDGE, DUBLIN 4, IRELAND 00000
353-1-268-2000

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture. Its Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution.

Data derived from most recent annual or quarterly report
Market Cap 68.919 Million Shares Outstanding235.22 Million Avg 30-day Volume 71.191 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-3.07
Price to Revenue0.0009 Debt to Equity-0.0011 EBITDA102.593 Million
Price to Book Value0.0 Operating Margin3.5507999999999997 Enterprise Value-984.928 Million
Current Ratio3.105 EPS Growth0.922 Quick Ratio2.144
1 Yr BETA 1.8767 52-week High/Low 7.07 / 0.28 Profit Margin-12.1695
Operating Cash Flow Growth291.4667 Free Cash Flow to Firm (FCFF) TTM 77.412 Million Free Cash Flow to Equity (FCFE) TTM-38.101 Million
Altman Z-Score-2.9117
View SEC Filings from ENDPQ instead.

View recent insider trading info

Endo International plc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ENDPQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENDPQ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-08-17 by TURSI JAMES PATRICK
  • 4: filed on 2022-03-31 by BARRY PATRICK A
  • 4: filed on 2022-03-31 by RACITI FRANK B.
  • 4: filed on 2022-03-31 by MALETTA MATTHEW JOSEPH
  • 4: filed on 2022-03-31 by BRADLEY MARK T.
  • 4: filed on 2022-03-31 by COLEMAN BLAISE
  • 4: filed on 2022-03-08 by BARRY PATRICK A
  • 4: filed on 2022-03-08 by RACITI FRANK B.
  • 4: filed on 2022-03-08 by BRADLEY MARK T.
  • 4: filed on 2022-03-08 by COLEMAN BLAISE

    • Events (8k)

  • 8-K: filed on 2023-11-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-02:
    Item 8.01: Other Events
  • 8-K: filed on 2023-09-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-01:
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-29:
    Item 8.01: Other Events
  • 8-K: filed on 2023-05-30:
    Item 8.01: Other Events
  • 8-K: filed on 2023-05-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-31:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TURSI JAMES PATRICK EXECUTIVE VP, GLOBAL R&D

    • Officer
    		 0 2022-07-15 0

    MALETTA MATTHEW JOSEPH EVP, CLO & COMPANY SECRETARY

    • Officer
    		 1,095,316 2022-03-29 0

    COLEMAN BLAISE PRESIDENT, CEO

    • Officer
    • Director
    		 2,160,943 2022-03-29 0

    BARRY PATRICK A EVP & PRES,GLOBAL COMM OPS

    • Officer
    		 614,266 2022-03-29 0

    BRADLEY MARK T. EVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 436,336 2022-03-29 0

    RACITI FRANK B. VP, CONTROLLER AND CAO

    • Officer
    		 8,821 2022-03-29 0

    HYATT MICHAEL

    • Director
    		 355,560 2021-06-11 0

    MONTAGUE WILLIAM P

    • Director
    		 122,025 2021-06-11 0

    HUTSON NANCY J

    • Director
    		 116,140 2021-06-11 0

    COOKE SHANE

    • Director
    		 100,034 2021-06-11 0

    BARBERIO MARK G

    • Director
    		 38,187 2021-06-11 0

    CHAO JENNIFER M

    • Director
    		 24,921 2021-06-11 0

    SMITH MARY CHRISTINE

    • Director
    		 32,819 2021-06-11 0

    APOSTOL GEORGE EVP, GLOBAL R&D

    • Officer
    		 7,331 2021-06-01 0

    CAMPANELLI PAUL

    • Director
    		 4,558,587 2021-04-02 0

    BOYLE JACK D. SVP, CONTROLLER

    • Officer
    		 120,918 2021-04-02 0

    CIARICO DOMENICO EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 55,958 2020-09-03 0

    COUGHLIN TERRANCE J EVP, CHIEF OPERATING OFFICER

    • Officer
    		 356,644 2020-08-10 0

    GARELLA RAHUL EVP, INTL PHARMACEUTICALS

    • Officer
    		 55,244 2020-08-10 0

    KIMMEL ROGER H

    • Director
    		 216,575 2020-06-12 0

    NICHOL CARRIE ANN SVP, CONTROLLER & CAO

    • Officer
    		 14,096 2019-08-10 0

    MANSUKANI SHARAD

    • Director
    		 71,523 2019-06-12 0

    PERA ANTONIO R PRESIDENT, PAR PHARMACEUTICAL

    • Officer
    		 65,648 2019-04-02 0

    RUDIO DANIEL SVP, CONTROLLER

    • Officer
    		 9,669 2018-02-23 0

    INGRAM DOUGLAS S

    • Director
    		 17,336 2017-06-09 0

    SMITH JILL D.

    • Director
    		 43,719 2017-06-09 0

    UPADHYAY SUKETU EVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 22,412 2016-09-24 0

    CIAFFONI JOSEPH PRESIDENT, U.S. BRANDED PHARMA

    • Officer
    		 17,452 2016-08-16 0

    HIGGINS ARTHUR J

    • Director
    		 50,623 2016-05-11 0

    SISITSKY TODD BENJAMIN

    • Director
    		 0 2016-05-05 0

    VARGHESE HEMANTH JACOB PRES. INTERNATIONAL PHARMA

    • Officer
    		 4,350 2016-04-29 0

    DE SILVA RAJIV PRESIDENT & CEO

    • Officer
    • Director
    		 355,010 2016-03-18 0

    SPENGLER WILLIAM

    • Director
    		 48,835 2016-03-17 0

    HALL SUSAN EVP, CSO, GLOBAL HEAD OF R&D

    • Officer
    		 4,826 2016-03-11 0

    LORTIE BRIAN PRESIDENT BRANDED PHARMA

    • Officer
    		 24,504 2016-03-02 0

    MANOGUE CAROLINE B EXEC. V.P.,CHIEF LEGAL OFFICER

    • Officer
    		 133,302 2015-04-07 0

    FARHAT CAMILLE PRESIDENT, AMS, INC.

    • Officer
    		 0 2015-03-10 0

    DELUCCA JOHN

    • Director
    		 32,343 2015-03-04 0

    DEGOLYER DONALD W CHIEF OPERATING OFFICER,PHARMA

    • Officer
    		 6,547 2015-02-26 0

    GERGEL IVAN P. EVP, R&D AND CSO

    • Officer
    		 79,980 2014-03-10 0

    NASH DAVID

    • Director
    		 11,859 2013-12-31 0

    LEVIN ALAN G EVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 69,431 2013-06-01 0

    SCODARI JOSEPH C

    • Director
    		 6,515 2013-03-12 0

    MCHUGH JULIE CHIEF OPERATING OFFICER

    • Officer
    		 48,046 2013-03-08 0

    HOLVECK DAVID PRESIDENT & CEO

    • Officer
    • Director
    		 29,528 2013-02-26 0

    SWEENEY EDWARD J PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 17,406 2011-03-03 0

    MEANWELL CLIVE

    • Director
    		 11,855 2010-03-12 0

    D. E. SHAW VALENCE PORTFOLIOS, L.L.C.

    D. E. SHAW & CO, L.P.

    SHAW DAVID E

    • 10% Owner
    • SEE FOOTNOTE 4.SEE FOOTNOTE 4.SEE FOOTNOTE 4.
    		 No longer subject to file 2009-03-05 0

    WYSENSKI NANCY CHIEF OPERATING OFFICER

    • Officer
    		 13,054 2009-02-26 0

    DE ROSEN MICHEL

    • Director
    		 No longer subject to file 2008-06-30 0

    HORNER GEORGE F III

    • Director
    		 5,003 2008-03-12 0

    LEE DAVID A H EXEC. V.P AND CSO

    • Officer
    		 2,801 2008-02-21 0

    LAVISCOUNT JOYCE N CHIEF ACCOUNTING OFFICER

    • Officer
    		 3,275 2008-02-21 0

    ROWLAND CHARLES A JR EVP, CFO & TREASURER

    • Officer
    		 6,699 2008-02-21 0

    LANKAU PETER A PRESIDENT & CEO

    • Officer
    • Director
    		 1,029,263 2006-12-04 0

    AMMON CAROL A

    • Director
    		 603,614 2006-11-29 0

    CLINGEN BRIAN T

    • DIRECTOR UNTIL 3/15/2006
    		 28,750 2006-03-27 0

    MITCHELL MICHAEL W

    • DIRECTOR UNTIL 3/15/2006
    		 36,250 2006-03-27 0

    O DONNELL JOSEPH T JR

    • Director
    		 35,000 2006-03-27 0

    NICKELL FRANK T

    BERNEY PHILIP E

    BYNUM FRANK K

    GOLDBERG MICHAEL B

    LOVERRO FRANK J

    MATELICH GEORGE E

    SCHUCHERT JOSEPH S

    WAHRHAFTIG DAVID I

    WALL THOMAS R IV

    CONNORS JAMES J II

    • Director
    • 10% Owner
    • MD OF OWNER DIRECTOR OF ISSUER
    		10,236,668 2006-03-07 0

    KELSO INVESTMENT ASSOC V L P

    BERNEY PHILIP E

    BYNUM FRANK K

    GOLDBERG MICHAEL B

    LOVERRO FRANK J

    MATELICH GEORGE E

    SCHUCHERT JOSEPH S

    WAHRHAFTIG DAVID I

    WALL THOMAS R IV

    CONNORS JAMES J II

    • Director
    • 10% Owner
    • MD OF OWNER DIRECTOR OF ISSUER
    		10,126,394 2006-03-07 0

    KELSO EQUITY PARTNERS V L P

    BERNEY PHILIP E

    BYNUM FRANK K

    GOLDBERG MICHAEL B

    LOVERRO FRANK J

    MATELICH GEORGE E

    SCHUCHERT JOSEPH S

    WAHRHAFTIG DAVID I

    WALL THOMAS R IV

    CONNORS JAMES J II

    • Director
    • 10% Owner
    • MD OF OWNER DIRECTOR OF ISSUER
    		10,126,394 2006-03-07 0

    KELSO PARTNERS V L P

    BERNEY PHILIP E

    BYNUM FRANK K

    GOLDBERG MICHAEL B

    LOVERRO FRANK J

    MATELICH GEORGE E

    SCHUCHERT JOSEPH S

    WAHRHAFTIG DAVID I

    WALL THOMAS R IV

    CONNORS JAMES J II

    • Director
    • 10% Owner
    • MD OF OWNER DIRECTOR OF ISSUER
    		9,340,455 2006-03-07 0

    ENDO PHARMA LLC

    • MGR OF OWNER DIRECT. OF ISSUER
    		 13,409,811 2006-03-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 22:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 21:45:03 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 21:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 20:45:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 20:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 19:45:03 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 19:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 18:45:03 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 18:15:03 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 17:45:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 17:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 16:45:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 16:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 15:45:03 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 15:15:03 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 14:45:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 14:15:04 UTC -1.1387 6.4587 7700000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 13:45:04 UTC -1.1387 6.4587 7100000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 13:15:03 UTC -1.1387 6.4587 7100000
    ENDO INTERNATIONAL PLC ENDPQ 2023-11-28 12:45:04 UTC -1.1387 6.4587 7100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund ENDPQ -763.0 shares, $-2823.1 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund ENDPQ -633.0 shares, $-2342.1 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund ENDPQ -927.0 shares, $-3429.9 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments